Gaublomme, Jellert T.
Li, Bo http://orcid.org/0000-0003-0668-1620
McCabe, Cristin
Knecht, Abigail
Yang, Yiming http://orcid.org/0000-0002-0386-9428
Drokhlyansky, Eugene
Van Wittenberghe, Nicholas
Waldman, Julia
Dionne, Danielle http://orcid.org/0000-0002-8338-4323
Nguyen, Lan
De Jager, Philip L. http://orcid.org/0000-0002-8057-2505
Yeung, Bertrand
Zhao, Xinfang
Habib, Naomi
Rozenblatt-Rosen, Orit
Regev, Aviv
Article History
Received: 10 December 2018
Accepted: 22 May 2019
First Online: 2 July 2019
Change Date: 2 November 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing interests
: A.R. is a SAB member of ThermoFisher Scientific and Syros Pharamceuticals and a founder and equity holder of Celsius Therapeutics. B.Y. and X.Z. are employees of Biolegend which produces the NPC antibodies used in this assay. A.R., O.R.R., J.G., and B.L. are inventors on a pending patent application PCT/US2018/064563. The patent applicants are the Broad Institute, Inc. and MIT. The patent covers the nucleus-hashing protocol and the DemuxEM algorithm described in this paper. The remaining authors declare no competing interests.